Please login to the form below

Not currently logged in
Email:
Password:

Moderna

This page shows the latest Moderna news and features for those working in and with pharma, biotech and healthcare.

Richest countries are on course to purchase one billion excess COVID-19 vaccines, new analysis finds

Richest countries are on course to purchase one billion excess COVID-19 vaccines, new analysis finds

Report from the ONE Campaign considered vaccine supply deals agreed by G20 countries and the EU

Latest news

More from news
Approximately 39 fully matching, plus 97 partially matching documents found.

Latest Intelligence

  • Rare genetic diseases – what’s in store for 2021? Rare genetic diseases – what’s in store for 2021?

    So far the Pfizer/BioNTech, Moderna and AstraZeneca/Oxford University vaccines have all received approval in the UK and other countries for the very disease that put all these changes into

  • COVID-19: the race to find a vaccine COVID-19: the race to find a vaccine

    Moderna was the first group to test a vaccine in humans, using its mRNA platform to enter the clinic in record time. ... Moderna thinks its vaccine could be available to healthcare professionals as early as the autumn, but the accepted timeline for

  • Developing a COVID-19 vaccine Developing a COVID-19 vaccine

    At the front of the race is Cambridge, Massachusetts-based biotech company Moderna, which dosed the first patient in the US in March with its COVID-19 vaccine candidate. ... To win approval for public use, a larger phase 2 trial is need, which Moderna

  • Deal Watch September 2016 Deal Watch September 2016

    Abbott, Allergan, Celgene, Moderna, Pfizer and Takeda feature in this month's pharma deals round-up. ... up. Turning to the battle against the Zika virus, BARDA announced three more grants for vaccine development to Takeda (up to $312m), Moderna [up to

  • Deal Watch June 2016 Deal Watch June 2016

    Apart from the $200m upfront cash payment to Moderna, there were no other financials disclosed. ... licence. 230. Moderna Therapeutics/ Merck &Co. mRNA-based personalised cancer vaccines; exclusive for Keytruda combinations (discovery).

More from intelligence
Approximately 1 fully matching, plus 9 partially matching documents found.

Latest appointments

More from appointments
Approximately 3 fully matching, plus 6 partially matching documents found.

Latest from PMHub

  • Clinical trials and the diversity principle Clinical trials and the diversity principle

    The following month, it happened again. Cambridge, Massachusetts-based Moderna said it had slowed enrolment in its phase 3 COVID-19 vaccine trial to ensure they were getting a representative population. ... Moderna effectively sacrificed potential sales,

  • Mistrust in medical research: a patient perspective

    15]. In fact, Moderna slowed down recruitment for its COVID-19 vaccine trial specifically to address a shortfall in recruitment from ethnically diverse populations for an illness that has been shown

  • Is the world ready for a COVID-19 vaccine? Is the world ready for a COVID-19 vaccine?

    Since then, other good news has followed, with collaborations, including Moderna and AstraZeneca, publishing similarly positive results. ... Since this initial announcement, other good news in vaccine development has followed, with companies and

  • Hanover Communications Hanover Communications

    Since then, other good news has followed, with collaborations, including Moderna and AstraZeneca, publishing similarly positive results.

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...
#DemandDiversity: Black history in clinical trials: It's more than just Tuskegee [Infographic]
Take a look at this infographic showing some of the most notorious clinical trials and medical research in history....

Infographics